FDA advisers endorse Eli Lilly's Alzheimer's drug, donanemab, for potential approval.
FDA advisers have endorsed Eli Lilly's experimental Alzheimer's drug, donanemab, for potential approval, after determining its benefits in slowing the disease outweigh risks like brain swelling and bleeding. If approved, donanemab would become the second Alzheimer's drug in the U.S. that slows cognitive decline and memory problems due to Alzheimer's. The FDA will make the final decision on approval later this year.
June 10, 2024
50 Articles